Novo Nordisk narrows 2026 adjusted sales outlook to -6% to flat; U.S.-traded shares drop more than 5%
AI Market Summary
Novo Nordisk's U.S.-traded shares fell over 5% after 2026 guidance still implies adjusted sales and operating profit down 6% to flat, despite a modest upward revision. Management flagged weakening U.S. trends for GLP-1 injectables, intensifying competition, Medicaid coverage pressure, and lower realized prices tied to a "most favored nation" pricing agreement. The update increases scrutiny on GLP-1 growth durability and near-term margin resilience.
Impact level
● Medium
Affected assets
NCSKNVO2USD/USDT-5.57%
AI Insight · NCSKNVO2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Novo Nordisk issued 2026 guidance projecting adjusted sales to range from down 6% to flat at constant exchange rates, narrowing from its earlier forecast of down 4% to 12%. It also set its 2026 adjusted operating profit outlook at down 6% to flat, and reported adjusted sales growth of 7% for the first half and second quarter of 2026. The update raised concerns about the durability of GLP-1 growth, sending its U.S.-traded shares down more than 5% in a single session.
